Corona Remedies IPO — Everything You Need to Know

Pharma company Corona Remedies is coming out with its IPO from December 8 to December 10. The price band is ₹1,008–₹1,062 per share and the IPO size is ₹655.37 crore (Offer For Sale). Since it’s entirely an OFS, no fresh money goes to the company — the existing investors and promoters will sell their shares. Important Dates • Anchor Investors: Dec 5 • Public Issue: Dec 8–10 • Listing: Dec 15 Company Snapshot • Pharma company based in Ahmedabad • Focus areas: Women’s health, diabetes, pain care, cardiology, urology • 67 brands under its portfolio • One of the fastest-growing domestic pharma companies • Reported 16.77% growth CAGR vs industry growth of 9.21% (Jun 2022–Jun 2025) Issue Allocation • QIB: 50% • Retail: 35% • HNI: 10% Why This IPO Looks Attractive • Strong growth in domestic pharma business • Established brand portfolio • Growing focus on women’s healthcare and lifestyle diseases (high demand categories) • Backed by reputed investor ChrysCapital Risks to Consider • OFS issue → company will not receive funds for expansion • Pharma industry faces regulatory challenges and pricing pressure • Market competition is high with many established players Takeaway Corona Remedies is a fast-growing domestic pharma player with strong brands and steady growth. However, since the IPO is 100% OFS, investors should evaluate valuation and listing demand before applying.